What is the prevalence of Scleroderma?

The prevalence of systemic scleroderma is estimated to be between 7 and 489 cases per million individuals worldwide, though these figures vary significantly by geographic region and study methodology.

Epidemiological Overview

While Scleroderma is classified as a rare disease, its incidence and prevalence are not uniform. The annual incidence of systemic Scleroderma is generally estimated at 8 to 56 cases per million people. Because these figures rely on clinical registries, they likely underestimate the true burden of disease due to frequent underdiagnosis or misdiagnosis in early, mild, or localized cases.

Demographics and Variations

• Gender and Age: Scleroderma exhibits a marked female predominance, with women being affected three to four times more often than men. While it can occur at any age, the peak age of onset for systemic Scleroderma is typically between 30 and 50 years; pediatric-onset cases are rare but well-documented.


• Geographic and Ethnic Factors: Data from the NIH GARD indicates that prevalence appears higher in North America and parts of Europe compared to Asia. Furthermore, certain ethnic groups, such as those of African descent, may experience more severe disease manifestations and earlier onset.

Data Challenges and Community Perspectives

Accurately mapping Scleroderma is complicated by the distinction between localized forms (morphoea) and systemic sclerosis, as well as the variability in diagnostic criteria used over the last several decades. Real-world insights, such as those shared by the 1,110 members of the DiseaseMaps.org community, provide a vital, complementary perspective to clinical data. These patient-reported experiences highlight the lived reality of navigating a complex condition that often takes years to diagnose correctly. By aggregating these individual experiences, we gain a clearer picture of the diagnostic delays and symptomatic patterns that formal epidemiological studies sometimes overlook.

Disclaimer: This information is for educational purposes and should not replace professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions regarding a medical condition.

References

• Orphanet: Systemic Sclerosis (ORPHA817)


• NIH Genetic and Rare Diseases Information Center (GARD): Scleroderma


• Scleroderma Foundation: Understanding Scleroderma